Antibody and cytokine study for people with CGD
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This study is checking levels of antibodies and immune-signaling molecules (cytokines) in people with chronic granulomatous disease (CGD). It aims to better understand the immune system in CGD, which may help with future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of chronic granulomatous disease (CGD).
- Your CGD diagnosis must be based on a specific lab test showing very low NADPH oxidase activity or a confirmed gene mutation.
- You or your legal guardian must be able to sign a consent form.
- You must be able to follow the study rules and give blood samples as needed.
- You cannot have had a bone marrow transplant or gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (SGX-001) for chronic granulomatous disease caused by a specific genetic change. The treatment tries to fix the gene in your immune cells so they can fight infections better, and the trial will follow participants for up to 15 years to make sure it's safe and effective.
This study looks at how the immune system works in people who have abnormal immune function, often shown by unusual or repeated infections or long-lasting inflammation. It may involve tests using blood samples and storage of blood for future research.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
This study tests a new gene therapy for people with a rare immune disorder called chronic granulomatous disease (CGD), which causes repeated infections. The treatment uses a modified virus to deliver a healthy gene to your blood stem cells, potentially helping your immune system fight off bacteria and fungi. The goal is to reduce the risk of severe infections and improve overall health.
This study tests a stem cell transplant using a special conditioning regimen to treat chronic granulomatous disease (CGD), a condition that causes repeated infections and inflammation. The transplant aims to replace faulty immune cells with healthy ones from a donor, potentially reducing infections and improving quality of life.
Hear when a new Chronic Granulomatous Disease (CGD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.